| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.68, 1.26] | | < 1 | | 69% | 2 studies (2/-) | 69.6 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.93 [0.59, 1.48] | | < 1 | | 87% | 2 studies (2/-) | 61.9 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 0.70 [0.46, 1.06] | | > 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| STRAE (any grade) | 1.25 [0.67, 2.31] | | < 1 | | 66% | 2 studies (2/-) | 24.2 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.27 [0.52, 3.13] | | < 1 | | 81% | 2 studies (2/-) | 30.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.83 [0.05, 13.17] | | < 1 | | 98% | 2 studies (2/-) | 55.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.70 [0.07, 7.49] | | < 1 | | 98% | 2 studies (2/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 4.33 [0.48, 39.16] | | < 1 | | 0% | 1 study (1/-) | 9.7 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.78 [0.52, 1.16] | | < 1 | | 0% | 2 studies (2/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.02 [0.62, 1.68] | | < 1 | | 0% | 2 studies (2/-) | 46.7 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.17 [0.00, 11.79] | | < 1 | | 94% | 2 studies (2/-) | 78.8 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.38 [0.05, 3.18] | | < 1 | | 9% | 2 studies (2/-) | 81.2 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.44 [0.04, 5.01] | | < 1 | | 0% | 2 studies (2/-) | 74.5 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.71 [0.13, 3.87] | | < 1 | | 41% | 2 studies (2/-) | 65.3 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.72 [0.23, 2.31] | | < 1 | | 0% | 2 studies (2/-) | 70.8 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.67 [0.06, 6.88] | | < 1 | | 86% | 2 studies (2/-) | 63.2 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.19 [0.36, 3.94] | | < 1 | | 0% | 1 study (1/-) | 39.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 3.51 [0.72, 17.07] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.52 [0.13, 2.03] | | < 1 | | 23% | 2 studies (2/-) | 82.5 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.17 [0.00, 11.82] | | < 1 | | 89% | 2 studies (2/-) | 78.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.98 [0.02, 49.83] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.68 [0.05, 8.94] | | < 1 | | 0% | 2 studies (2/-) | 61.3 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.49 [0.02, 14.72] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.03 [0.28, 14.47] | | < 1 | | 0% | 2 studies (2/-) | 24.1 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.97 [0.07, 59.09] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 12.07 [0.67, 217.19] | | < 1 | | 0% | 1 study (1/-) | 4.7 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 5.00 [0.58, 43.09] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.49 [0.02, 14.72] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.04 [0.01, 0.31] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.50 [0.04, 6.57] | | < 1 | | 61% | 2 studies (2/-) | 69.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Increase AST AE (grade 3-4) | 7.05 [0.86, 57.74] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
